• FAQS
  • ABOUT
  • LOG IN
  • SIGN UP

KMDA Overview

Upcoming Projects (KMDA) Image
  • Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (KMDA) Image
  • Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (KMDA) Image
  • KMDA's Phase 2 data for Alpha-1 Antitrypsin for Pediatric Patients newly diagnosed with Type 1 diabetes Expected Q3 2017
    Ticker: KMDA
    Occurred on: Jan 08, 2018
  • Kamada and Kedrion announce the filing of a BLA in the U.S. seeking approval of Kamada's post-exposure rabies treatment human anti-rabies immune globulin (IgG); decision expected mid-2017
    Ticker: KMDA
    Occurred on: Aug 25, 2017
  • Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency
    Ticker: KMDA
    Occurred on: Aug 30, 2016
  • Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
    Ticker: KMDA
    Occurred on: Apr 07, 2016
  • Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
    Ticker: KMDA
    Occurred on: Mar 28, 2016
Strategic Initiatives (KMDA) Image
  • Shire (SHPG) Extends Kamada's (KMDA) GLASSIA Supply Agreement Through 2020
    Tickers: KMDA, SHPG
    Announcement Date: Oct 06, 2016
About Us
  • About
  • Pricing
  • Compliance
  • Terms of Use
  • Privacy Policy
Media Center
  • Jobs
Connect with Us
  • facebook Facebook
  • facebook Twitter
  • facebook LinkedIn
  • facebook Email Us
© 2025 Slingshot Insights. All rights reserved.